Dual action tofacitinib-loaded PLGA nanoparticles alleviate colitis in an IBD mouse model DOI Creative Commons

Nidhi Seegobin,

Laura E. McCoubrey, Cécile Vignal

et al.

Drug Delivery and Translational Research, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 11, 2024

Abstract Inflammatory bowel disease (IBD) affects over 7 million people worldwide and significant side effects are associated with current therapies such as tofacitinib citrate (TFC), which is linked to increased risks of malignancy congestive heart issues. To mitigate these systemic adverse effects, localised drug delivery via nano-sized carriers inflamed gut tissues represents a promising approach. Herein, we aimed optimise the synthesis nanoparticles (NPs) using low molecular weight grade Poly(lactic-co-glycolic acid) (PLGA) 50:50 loaded TFC. This approach leverages dual anti-inflammatory action TFC local production short-chain fatty acids from degradation PLGA by colonic microbiota. NPs were produced nanoprecipitation characterised for their release profile in vitro. The efficacy enhanced PLGA-TFC was then tested C57BL/6 DSS colitis mouse model. showed 40% burst within first hour, followed up 80% environment. Notably, microbiota did not significantly influence release. In model, neither alone nor on loss compared TFC-loaded NPs, emphasising potential combined formulation. Altogether, results suggest role NP systems enhancing efficacy, marking step towards reducing dosage IBD treatment. study underscores providing targeted effective therapy IBD. Graphical

Language: Английский

Design of Poly(lactic-co-glycolic acid) nanoparticles in drug delivery by artificial intelligence methods to find the conditions of nanoparticles synthesis DOI
Bader Huwaimel,

Saad Alqarni

Chemometrics and Intelligent Laboratory Systems, Journal Year: 2025, Volume and Issue: unknown, P. 105335 - 105335

Published: Jan. 1, 2025

Language: Английский

Citations

4
Quercetin-Loaded Nanoparticle-Modified Decellularized Tissue-Engineered Vascular Graft Regulates Macrophage Polarization and Promotes In Vivo Graft Remodeling DOI Creative Commons
Tun Wang, Zhenyu He, Peng Lü

et al.

International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 2761 - 2778

Published: March 1, 2025

Arteriovenous graft (AVG) is an important option for establishing hemodialysis access in patients with end-stage chronic kidney disease (CKD). Decellularized tissue-engineered vascular (dTEVG), due to its excellent biocompatibility and regenerative potential, holds promise use AVG; however, poor remodeling remains a challenge. Quercetin (Qu) can effectively regulate macrophage polarization promote tissue regeneration, yet low bioavailability limits clinical application. Here, we developed nano-localized drug delivery system using Qu-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (Qu@PNPs), prepared via nanoprecipitation method subsequently modified onto the surface of dTEVG. In vitro vivo experiments were performed assess Qu@PNPs their effect on polarization. Additionally, impact modification dTEVG was evaluated both subcutaneous AVG rat models. Our study results demonstrated that exhibited good achieved sustained release Furthermore, these drug-loaded inhibited M1 while promoting M2 polarization, significantly improving dTEVG, as evidenced by increased early recellularization peripheral neovascularization. Together, development enhanced application Qu, providing experimental evidence it offers new strategies approaches optimizing design translation.

Language: Английский

Citations

0
Applications of Cyclodextrin-Based Drug Delivery Systems in Inflammation-Related Diseases DOI Creative Commons

Zelan Dai,

Huijuan Yang, Peng Yin

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(3), P. 378 - 378

Published: March 17, 2025

Currently, inflammation diseases are one of the leading causes mortality worldwide. The therapeutic drugs for mainly steroidal and non-steroidal anti-inflammatory drugs. However, use these over a prolonged period is prone to causing serious side effects. Accordingly, it particularly critical design an intelligent target-specific drug delivery system control release in order mitigate effects without limiting their activity. Meanwhile, cyclodextrin-based nano-delivery systems have garnered significant attention contemporary pharmaceutical research owing capacity enhance bioavailability, enable site-specific targeted accumulation, prolong systemic circulation duration, facilitate synergistic outcomes, exhibit superior biocompatibility profiles. It worth noting that show great potential inflammation-related diseases. few studies systematically reviewed strategies application advancements. Here, we summarize structural chemical modification cyclodextrins, as well applications In summary, aim provide bit insight into development

Language: Английский

Citations

0
Dual action tofacitinib-loaded PLGA nanoparticles alleviate colitis in an IBD mouse model DOI Creative Commons

Nidhi Seegobin,

Laura E. McCoubrey, Cécile Vignal

et al.

Drug Delivery and Translational Research, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 11, 2024

Abstract Inflammatory bowel disease (IBD) affects over 7 million people worldwide and significant side effects are associated with current therapies such as tofacitinib citrate (TFC), which is linked to increased risks of malignancy congestive heart issues. To mitigate these systemic adverse effects, localised drug delivery via nano-sized carriers inflamed gut tissues represents a promising approach. Herein, we aimed optimise the synthesis nanoparticles (NPs) using low molecular weight grade Poly(lactic-co-glycolic acid) (PLGA) 50:50 loaded TFC. This approach leverages dual anti-inflammatory action TFC local production short-chain fatty acids from degradation PLGA by colonic microbiota. NPs were produced nanoprecipitation characterised for their release profile in vitro. The efficacy enhanced PLGA-TFC was then tested C57BL/6 DSS colitis mouse model. showed 40% burst within first hour, followed up 80% environment. Notably, microbiota did not significantly influence release. In model, neither alone nor on loss compared TFC-loaded NPs, emphasising potential combined formulation. Altogether, results suggest role NP systems enhancing efficacy, marking step towards reducing dosage IBD treatment. study underscores providing targeted effective therapy IBD. Graphical

Language: Английский

Citations

1